SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

WorldFinancial

World Liberty Financial (WLFI) is trending as a U.S. House investigation into its $500 million investment deal with a UAE royal ignites a polarized community debate over its political implications and financial integrity. While proponents view the scrutiny as a buying opportunity ahead of anticipated product launches, skeptics dismiss the Trump-linked crypto venture as a "scam," fueling conversations around crypto regulation and market intervention.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending due to ongoing discussions around its Polkadot 2.0 rollout, which includes a pivotal shift to a capped 2.1 billion token supply and the Agile Coretime model designed to enhance network utility. While many express deep frustration over recent price performance, a strong bullish contingent highlights these fundamental upgrades and staking opportunities as a major re-rating catalyst attracting institutional interest.

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical, Risk, Legal Exhibitions and Print & print-related. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity. The Risk segment provides customers with solutions and decision tools that combine public and industry specific content with advanced technology and analytics to assist them in evaluating and predicting risk and enhancing operational efficiency. The Legal segment is a global provider of legal, regulatory and business information and analytics that helps customers increase productivity, improve decision-making and outcomes and advance the rule of law around the world. The Exhibitions segment is an event business, enhancing the effect of face-to-face through data and digital tools. The Print & print-related segment consistent with financial information provided to the board. The company was founded by Albert Edward Reed in 1903 and is headquartered in London, the United Kingdom.

RELX Plc - ADR

RELX is a focal point of discussion as fears of AI disruption from new legal tools cause a sell-off, while a segment of the community views the dip as a prime opportunity to invest in its high-quality, data-moat business, emphasizing its strong AI integration and ongoing share buyback program.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid an FDA crackdown and DOJ referral over its compounded GLP-1 weight-loss drugs, sparking a heated debate between investors concerned about regulatory risks and those who view the company as a disruptive force challenging big pharma for affordable healthcare.

BlackRock Institutional Trust Company N.A. - iShares China Large-Cap ETF

iShares China Large-Cap ETF

FXI is actively discussed as investors weigh a significant trade surplus and recent policy support against concerns over manufacturing contraction and a struggling property sector. The community is watching for further clarity from ongoing US-China trade discussions and potential stimulus, which could drive a broader rally in Chinese equities.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera (HBAR) is trending amid strong community debate, propelled by recent announcements of its U.S. military adoption for quantum-secure drones and its prominent role at the World Economic Forum, sparking both deep conviction in its Real World Asset utility and skepticism over tokenomics in a volatile market.

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Pulse Biosciences Inc

Pulse Biosciences is trending due to its FDA Breakthrough Device Designation for the CellFX nsPFA Cardiac Surgery System and positive clinical data from first-in-human studies. The community is actively discussing the game-changing potential of its nanosecond Pulsed Field Ablation platform technology across multiple medical applications, reinforced by notable insider buying.

Lighter is a decentralized trading platform built for unmatched security and scale. It’s the first exchange to offer verifiable order matching and liquidations while delivering best-in-class performance on par with traditional exchanges.

lighter

LIT (Lighter) is trending as investors debate strong bullish catalysts like a new Indodax listing and mandatory staking creating a supply squeeze against community concerns over its reported Coinbase delisting and upcoming rebrand to HEI.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and decor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending following its recent mixed earnings, which revealed a lowered profit outlook and soft demand for big-ticket projects, sparking community discussion around the unusual "lack of storms" commentary. Despite current consumer uncertainty, many investors are actively anticipating a housing market rebound driven by potential rate cuts, fueling bullish options activity and highlighting Home Depot's long-term strategic investments in its Pro ecosystem and AI tools.

GhostwareOS (GHOST) is the Full-Stack Privacy Layer of Solana — a next-generation AI-driven infrastructure for encrypted communication, anonymous identity management, and untraceable transactions. By combining advanced zero-knowledge protocols with autonomous AI routing, GhostwareOS allows users and developers to operate invisibly across Web3. It powers decentralized apps that demand true digital anonymity, scalable privacy, and zero metadata leakage — restoring control to users in an overexposed internet age.

Ghost

GHOST CRYPTO is trending as a high-potential privacy project on Solana, fueled by recent integrations like the Solflare wallet and ongoing discussions about its utility, low market cap, and upcoming revenue share. Community members are actively speculating on its decoupling from broader market trends and significant growth, viewing it as an early gem in the privacy narrative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PTN Response to Big1: I was in Pharma sales 14 years. These days, companies rarely launch a massive marketing campaign the moment a drug is approved. I’ve seen large companies hire and train salesforces for “sure thing” drugs... that fda rejected. That’s a massive blow to big companies, devastating to small ones. Too risky to build that infrastructure before approval. It takes time post-approval to hire/train a sales force. This cannot be rushed. It is highly regulated. If poorly trained reps market a drug improperly, the company can be fined and marketing halted. 
Also, DTC advertising before physicians have been widely trained on a product is frowned upon both by physicians and FDA.  It can be done, but sparingly. So far, the lack of advertising is unsurprising to me. if it does not ramp up soon, however, we should begin to expect manipulative efforts.

Steph b

don boonstra

Michael

ma_cgy

KnysnaNow

nomada

MileHighBull

ishbehavior

Pomaikai

dkngbagholder

Nat S

Lotusman

OCUGENLIFER

Don Widener

Brad Lester

big R

Loren Carmichael

Ian Smith

StockTwits Web

Palatin Technologies Inc.

 Response to Big1: I was in Pharma sales 14 years. These days, companies rarely launch a massive marketing campaign the moment a drug is approved. I’ve seen large companies hire and train salesforces for “sure thing” drugs... that fda rejected. That’s a massive blow to big companies, devastating to small ones. Too risky to build that infrastructure before approval. It takes time post-approval to hire/train a sales force. This cannot be rushed. It is highly regulated. If poorly trained reps market a drug improperly, the company can be fined and marketing halted. 
Also, DTC advertising before physicians have been widely trained on a product is frowned upon both by physicians and FDA.  It can be done, but sparingly. So far, the lack of advertising is unsurprising to me. if it does not ramp up soon, however, we should begin to expect manipulative efforts.

Matt Whisnant

Now mind you, what I said explains the lack of widespread promotion and DTC advertising. I do find the stock price somewhat suspicious. Another thing I saw first hand in my 14 years in pharma was ”inexplicable“ actions (or inaction) by execs that suppressed share price. Usually, it preceded a buyout. The suppressive actions, I realized in retrospect, had served to keep the share price in a range that pleased a pre-determined buyer. I have no insider knowledge here, but I would be very surprised if a major pharma company does not scoop this up. With Big Pharma marketing muscle— and Big Pharma R&amp;D budgets to initiate a trial for males— this drug has limitless potential, in my opinion. Limitless. That’s why I’m long.

Now mind you, what I said explains the lack of widespread promotion and DTC advertising. I do find the stock price somewhat suspicious. Another thing I saw first hand in my 14 years in pharma was ”inexplicable“ actions (or inaction) by execs that suppressed share price. Usually, it preceded a buyout. The suppressive actions, I realized in retrospect, had served to keep the share price in a range that pleased a pre-determined buyer. I have no insider knowledge here, but I would be very surprised if a major pharma company does not scoop this up. With Big Pharma marketing muscle— and Big Pharma R&D budgets to initiate a trial for males— this drug has limitless potential, in my opinion. Limitless. That’s why I’m long.

@Growthparadigm   It is all about the hype....not even approved yet and this stock EXPLODED..up over 200 percent(KRTX)
While your statement may be true, it is weak if you are here to make money...This is a bloated penny stock, look for a reverse split soon after dilution.  Retail has lost out on this....
meanwhile, sorry you did not get to ride the KRTX train today, but the drug may come  in handy for you one day....LOLOLOLOL

KARUNA THERAPEUTICS SHARES RIP HIGHER AFTER SCHIZOPHRENIA DRUG ACES MIDSTAGE TRIAL
For further details see: Karuna Therapeutics Shares Rip Higher After Schizophrenia Drug Aces Midstage Trial
News Provided by Benzinga via QuoteMedia

   It is all about the hype....not even approved yet and this stock EXPLODED..up over 200 percent(KRTX)
While your statement may be true, it is weak if you are here to make money...This is a bloated penny stock, look for a reverse split soon after dilution.  Retail has lost out on this....
meanwhile, sorry you did not get to ride the KRTX train today, but the drug may come  in handy for you one day....LOLOLOLOL

KARUNA THERAPEUTICS SHARES RIP HIGHER AFTER SCHIZOPHRENIA DRUG ACES MIDSTAGE TRIAL
For further details see: Karuna Therapeutics Shares Rip Higher After Schizophrenia Drug Aces Midstage Trial
News Provided by Benzinga via QuoteMedia

Stellar Lumens

Internet Computer

Keeta

U.S Oil

Sidney Cain

@LDRunner You suggest that somethkng KRTX did ensured their share price gains upon good news. What specifically did they do? And specifically what has PTN done to suppress similar share growth? I’m not trolling, and while I have ideas, I don’t know the answer. If you do, please explain.

 You suggest that somethkng KRTX did ensured their share price gains upon good news. What specifically did they do? And specifically what has PTN done to suppress similar share growth? I’m not trolling, and while I have ideas, I don’t know the answer. If you do, please explain.